An open-label, Phase 3 trial of TAK-003, a live attenuated dengue tetravalent vaccine, in healthy US adults: immunogenicity and safety when administered during the second half of a 24-month shelf-life

• Main Authors: Sanjay S. Patel (Author), Peter Winkle (Author), Alice Faccin (Author), Francesco Nordio (Author), Inge LeFevre (Author), Claudia Galindo Tsoukas (Author)
• Format: Book
• Published: Taylor & Francis Group, 2023-08-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Dengue is caused by a mosquito-transmitted flavivirus. The disease is now endemic to many tropical and subtropical regions, manifesting as approximately 96 million symptomatic cases of dengue each year. Clinical trials have shown TAK-003 (Qdenga®), a live attenuated dengue tetravalent vaccine, to be...